X0306 4 2020-06-30 1 0001722271 Akouos, Inc. AKUS 0001297709 Novartis Bioventures Ltd FORUM 1-1.32, LICHTSTRASSE 35 BASEL V8 CH-4056 SWITZERLAND 0 0 0 1 Former 10% Owner 0001114448 NOVARTIS AG FORUM 1-1.32, LICHTSTRASSE 35 BASEL V8 CH-4056 SWITZERLAND 0 0 0 1 Former 10% Owner Common Stock 2020-06-30 4 C 0 856262 A 856262 I See Footnote Common Stock 2020-06-30 4 C 0 199996 A 1056258 I See Footnote Common Stock 2020-06-30 4 P 0 125000 17.00 A 1181258 I See Footnote Series A Preferred Stock 2020-06-30 4 C 0 856262 0.00 D Common Stock 856262 0 I See Footnote Series B Preferred Stock 2020-06-30 4 C 0 199996 0.00 D Common Stock 199996 0 I See Footnote On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities. On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Novartis Bioventures Ltd., By: /s/ Bart Dzikowski, Title: Secretary of the Board, By: /s/ Beat Steffen, Title: Authorized Signatory 2020-07-02 Novartis AG, By: /s/ Bart Dzikowski, Title: Authorized Signatory, By: /s/ Beat Steffen, Title: Authorized Signatory 2020-07-02